博济医药：“卿芷软膏”获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Boji Pharmaceutical's subsidiary has received approval for a clinical trial of a new drug, "Qingzhi Ointment," from the National Medical Products Administration [1] - As of January to June 2025, Boji Pharmaceutical's revenue composition shows that 99.46% comes from services, while other businesses account for 0.54% [1] - The current market capitalization of Boji Pharmaceutical is 3.9 billion yuan [1] Group 2 - The article also mentions that prior to the arrest of the chairman of Peking University Pharmaceutical, police had investigated the group's factory, indicating potential issues within the company [1] - Internal sources suggest that the group's assets have been disposed of by the chairman, with significant funds remaining unaccounted for [1]